TickerTalks
Browse all tickers →
TickerTalks›$ROIV
ROROIV

Roivant Sciences Ltd.

$ROIV·$24B·Biotechnology·Healthcare
$33.53-1.5%YTD+53.6%1Y+96.0%
Price updated 1d ago·X counts updated 6d ago
ROROIV
$ROIVRoivant Sciences Ltd.
$33.53-1.50%75 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $ROIV on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

75X posts · last 7 days
Sep 30Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $ROIV's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data27 posts analyzed · as of 2026-09-15

Roivant popped +20% adding ~$5B in market cap after the PHocus Phase 2 in PH-ILD hit primary and key secondary endpoints (PVR p<0.0001, 6MWD p=0.0027, NT-proBNP p=0.0002). Cantor pegs $4–5B peak sales for mosliciguat in PH-ILD alone with Phase 3 probability at 80-90%. The chatter also expects Roivant to sweep up the rest of IMVT sooner rather than later.

Read what X is saying about $ROIV

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $ROIV — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventAcceleratingAI verdict · as of 2026-10-02

The move is getting stronger, with heavier trading behind it.

Roivant Sciences up 64% YTD — PHocus Phase 2 win, mosliciguat $4-5B peak sales, LISRAYA launch next.

Roivant Sciences is a biopharmaceutical conglomerate — Immunovant, Priovant, Genevant, Lysrelta plus a growing commercial-stage pipeline. The stock is up 64% YTD and 74% of its 52-week range on specific clinical breakout.

  • The P&L is pre-commercial at scale: revenue fell 33.5% YoY to $1.4M last quarter at a -25,381% operating margin — standard holding-company P&L; the FY27 EPS estimate at -$0.41 reflects the ongoing clinical-stage investment.
  • The specific commercial anchor: PHocus Phase 2 in PH-ILD hit primary and key secondary endpoints (PVR p<0.0001, 6MWD p=0.0027, NT-proBNP p=0.0002); Cantor pegs $4-5B peak sales for mosliciguat with Phase 3 probability at 80-90%.
  • LISRAYA launch and multiple pipeline readouts in the next quarters are the catalyst setup; the +20% +$5B market cap move post-PHocus is the specific technical confirmation.

Accelerating holds while mosliciguat Phase 3 initiation proceeds and the Immunovant acquisition sweep completes. A soft Nov 9 earnings print on cash runway, or any specific mosliciguat Phase 3 enrollment delay commentary, is what cools the move; a signed Immunovant acquisition close plus a FY27 revenue guide-up is what extends the breakout further.

Agrees with X sentimentX bulls on +20% +$5B market cap PHocus Phase 2 win (PVR p<0.0001, 6MWD p=0.0027, NT-proBNP p=0.0002), Cantor $4-5B peak sales with 80-90% Phase 3 probability, and the IMVT sweep framing have the specific setup right — this is a legitimate catalyst-driven biotech breakout.

What to watch: Nov 9 earnings — mosliciguat Phase 3 initiation, Immunovant acquisition progress, LISRAYA launch preparation, cash runway. A soft Phase 3 enrollment or IMVT acquisition stall is what cools the breakout.

On the calendar: 2026-11-09 — Q2 FY27 earnings

Read the AI verdict on $ROIV

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Biopharma holding company incubating and spinning out drug programs across multiple specialist subsidiary 'Vants.'

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ROIV.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $ROIV

Neutral — Biopharma holding company incubating and spinning out drug programs across multiple specialist subsidiary 'Vants.'

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-91.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-27.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-181%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-3.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
3322.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-6.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
81.2%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.33$-0.30-10.1%
Q1 2026May 20, 2026$-0.28$-0.29+3.5%
Q4 2025Feb 6, 2026$-0.24$-0.30+19.9%
Q3 2025Nov 10, 2025$-0.20$-0.32+36.9%
Next earningsMon, Nov 9·consensus EPS $-0.37

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$1.4M-33.5%80.3%-25381%$-0.26$-263.8M
Q4 FY25$2.5M-66.7%87.3%-14087%$0.43$-165.1M
Q3 FY25$2.0M-77.8%65.0%-16966%$-0.38$-191.5M
Q2 FY25$1.6M-64.9%92.9%-19493%$-0.17$-193.5M

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY27$52.1M$12.3M – $79.7M-$1.38-$2.22 – -$0.499
FY28$407.4M$181.8M – $570.0M-$1.31-$2.11 – -$0.479
FY29$1.5B$997.4M – $2.1B-$0.45-$1.35 – $1.057
FY30$3.3B$1.7B – $4.8B$1.34$0.48 – $2.163
FY31$5.5B$2.8B – $8.1B$2.98$1.07 – $4.804

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.65%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-8.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+8.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 581.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.105-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellOct 1Melissa B, EpperlyDirector17.8K sh$641KSellSep 30Eric VenkerCEO200.0K sh$7.3MSellSep 15Melissa B, EpperlyDirector4.9K sh$196KSellSep 15Meghan FitzgeraldDirector5.1K sh$203KSellSep 8Meghan FitzgeraldDirector20.0K sh$798KSellAug 28Eric VenkerCEO200.0K sh$7.2MSellAug 21Mayukh SukhatmePresident144.8K sh$5.3MSellAug 20Mayukh SukhatmePresident17.5K sh$653KSellAug 19Mayukh SukhatmePresident172.9K sh$6.4MSellAug 18Mayukh SukhatmePresident136.9K sh$5.0M
1–10 of 19
+ 37 other (15 inkinds · 13 exempts · 9 awards) in window

See when $ROIV insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentOct 5SC 13D/A
8-KShareholder voteSep 188-K — Item 5.07: Shareholder vote
AI summary

Roivant Sciences (ROIV) held its 2026 Annual General Meeting with 90.3% of outstanding shares participating. Shareholders re-elected Daniel Gold and Meghan FitzGerald as Class II directors and ratified Ernst & Young as the independent auditor. All management proposals passed with strong support. The high participation rate reflects institutional investor engagement in Roivant's governance as the company advances its biopharmaceutical pipeline.

8-KPress release / Reg FDSep 88-K — Item 7.01: Press release / Reg FD
AI summary

Roivant Sciences filed an 8-K on September 8, 2026, furnishing a press release under Reg FD (Item 7.01) announcing positive results from the PHocus clinical trial of mosliciguat, a next-generation soluble guanylate cyclase (sGC) stimulator, in pulmonary hypertension associated with interstitial lung disease (PH-ILD). The trial is conducted through Pulmovant Sciences, a Roivant subsidiary. The press release is furnished as Exhibit 99.1 and is not subject to Section 18 Exchange Act liability.

8-KPress release / Reg FDAug 278-K — Item 7.01: Press release / Reg FD
AI summary

Roivant Sciences (ROIV) filed the primary 8-K (Item 8.01) on August 27, 2026 announcing FDA approval of LISRAYA (brepocitinib) for the treatment of dermatomyositis -- a rare inflammatory muscle and skin disease. This is the first FDA-approved therapy specifically for dermatomyositis. The approval marks a major commercial milestone for Roivant and its partner Priovant Therapeutics.

+ 12 other (3 13Gs · 2 earnings 8-Ks · 2 proxys · 1 routine 8-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Roivant Sciences Ltd. $ROIV Stock Holdings Lowered by Assenagon Asset Management S.A.defenseworld.net·2d agoHead-To-Head Review: Janux Therapeutics (NASDAQ:JANX) and Roivant Sciences (NASDAQ:ROIV)defenseworld.net·12d agoRoivant’s Eric Venker sells 200,000 shares after option exercise (NASDAQ: ROIV)defenseworld.net·14d agoRoivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Monthsdefenseworld.net·20d agoRoivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Monthsmarketbeat.com·20d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · last 7 days

No standout posts about $ROIV on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport